GlaxoSmithKline Biologicals, 89 rue de l'Institut, 1330 Rixensart, Belgium.
Vaccine. 2009 Dec 30;27 Suppl 6:G67-71. doi: 10.1016/j.vaccine.2009.10.013.
A vaccine against malaria which complements existing control tools is an urgent medical need. RTS,S/AS, a pre-erythrocytic candidate vaccine, which targets the circumsporozoite protein, is the most advanced in clinical development. The safety, immunogenicity and efficacy of this candidate vaccine have been investigated in a series of trials in children and infants in endemic African countries. The vaccine shows promise for providing important public health benefits and a multicenter Phase III trial has started in Africa, aiming to further characterize the efficacy of the candidate vaccine and generate the regulatory data required for the licensing approval of the vaccine.
疟疾疫苗是一种迫切需要的医学手段，可以作为现有控制工具的补充。RTS,S/AS，一种针对环子孢子蛋白的原虫期候选疫苗，是临床开发中最先进的疫苗。该候选疫苗在非洲流行国家的一系列儿童和婴儿试验中已经进行了安全性、免疫原性和疗效的研究。该疫苗有望提供重要的公共卫生效益，一项多中心 III 期临床试验已经在非洲开始，旨在进一步确定候选疫苗的疗效，并为疫苗的许可批准生成所需的监管数据。
